Abstract
Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Current Drug Delivery
Title: Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Volume: 3 Issue: 1
Author(s): Rachna Rastogi, Yasmin Sultana, Asgar Ali and Mohammed Aqil
Affiliation:
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Abstract: Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Export Options
About this article
Cite this article as:
Rastogi Rachna, Sultana Yasmin, Ali Asgar and Aqil Mohammed, Particulate and Vesicular Drug Carriers in the Management of Tuberculosis, Current Drug Delivery 2006; 3 (1) . https://dx.doi.org/10.2174/156720106775197448
DOI https://dx.doi.org/10.2174/156720106775197448 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal QSAR Studies on NTF1836 Analogues as Mycothiol Biosynthesis Inhibitors
Letters in Drug Design & Discovery Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine Low-Cost Infertility Management
Current Women`s Health Reviews New Heterocyclic Hydrazones in the Search for Antitubercular Agents: Synthesis and In Vitro Evaluations
Letters in Drug Design & Discovery Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology Novel 2-hydrazino-pyrimidin-4(3H)-one Derivatives with Pseudofunctional- Similarity to Siderophores as Potential Antimycobacterial Agents
Medicinal Chemistry Inhibition Studies on Enzymes Involved in Isoprenoid Biosynthesis. Focus on Two Potential Drug Targets: DXR and IDI-2 Enzymes
Current Enzyme Inhibition Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Current Pharmaceutical Design Design, Synthesis and Evaluation of Antimicrobial Activity of Novel Oxazine Derivatives using Betti’s Protocol
Letters in Drug Design & Discovery Antimalarial Drug Development: Past to Present Scenario
Mini-Reviews in Medicinal Chemistry Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against <i>M. tuberculosis</i> Enzyme Targets
Current Topics in Medicinal Chemistry HPLC as a Tool in Medicinal Chemistry for the Monitoring of Tricyclic Antidepressants in Biofluids
Mini-Reviews in Medicinal Chemistry Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Review of Pediatric Uveitis
Current Pediatric Reviews Leishmanicidal Activity of New Megazol Derivatives
Medicinal Chemistry Synthesis, Characterization, and the Influence of Functionalized Multi-Walled Carbon Nanotubes with Sulfone Derivatives on the Gastric Cancer Cells
Current Nanoscience Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging